Eckert & Ziegler Strahlen- und Medizintechnik AG

  • WKN: 565970
  • ISIN: DE0005659700
  • Land: Deutschland

Nachricht vom 14.05.2019 | 16:21

Eckert & Ziegler will be admitted to the MSCI Germany Small Cap Index

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous

14.05.2019 / 16:21
The issuer is solely responsible for the content of this announcement.


Berlin, 14 May 2019. Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry will be admitted to the MSCI Germany Small Cap Index as of 28 May 2019. This decision was announced by MSCI Inc., a leading provider of research-based indexes, after its semi-annual index review for the MSCI equity indexes. In addition to the high transparency requirements of the Prime Standard, the Eckert & Ziegler shares thereby also fulfill the relevant index criteria such as market capitalization, momentum and yield.

"The strong increase in the value of the share over the past few quarters has confirmed our strategy to focus Eckert & Ziegler more on innovative pharmaceuticals for cancer treatment",
explained Dr. Andreas Eckert, CEO of Eckert & Ziegler AG. "We are delighted by the admission to the MSCI Germany Small Cap Index which will further raise the interest in our share and extend our presence in the capital markets."

The MSCI Germany Small Cap Index currently is composed by 113 companies of the German equity market.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



14.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Munich Re beschließt Aktienrückkauf

26. Februar 2020, 13:17

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

26. Februar 2020